

US AND Europe Diabetes Associated Eye Disorders Market Research Report Forecast to 2030

Market Report | 2023-12-24 | 122 pages | Market Research Future

AVAILABLE LICENSES:

- Single User Price \$2950.00
- Enterprisewide Price \$5250.00

Report description:

US AND Europe Diabetes Associated Eye Disorders Market Research Report Forecast to 2030

Market Overview

US AND Europe Diabetes Associated Eye Disorders Market is expected to register a notable CAGR of 6.46% during the review period. Diabetes-Associated Eye Disorders, also known as Diabetic Eye Diseases, refer to a group of eye conditions that can develop as complications of diabetes, particularly in individuals who have poorly managed blood sugar levels over an extended period.

The market growth is attributed to the rising prevalence of Diabetes, increasing awareness of ophthalmic diseases, and growing government initiatives.

Market Segmentation

Based on disease type, the US and Europe diabetes associated eye disorders market has been bifurcated into diabetic retinopathy and Diabetic Macular Edema (DME). The diabetic retinopathy segment dominated the market in 2022, while the diabetic macular edema (DME) segment is projected to be the faster-growing segment during the forecast period, 2023-2032.

On the basis of diagnosis & treatment, the US and Europe diabetes associated eye disorders market is bifurcated into diagnosis and treatment. The treatment segment dominated the market in 2022, as well as treatment segment is projected to be the faster-growing segment during the forecast period, 2023-2032.

On the basis of end user, the US and Europe diabetes associated eye disorders market is segmented into hospitals & clinics, ophthalmic centers, and others. The hospitals & clinics segment dominated the market in 2022, while the ophthalmic centers segment is projected to be the fastest-growing segment during the forecast period, 2023-2032.

Regional Analysis

The report on the US and Europe diabetes associated eye disorders market has been segmented based on Country/ Region as US, Europe

The US dominated the market for diabetes associated eye disorders in 2022, accounting for the largest revenue share of 52.82%.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Strong healthcare infrastructure, rising patient awareness of early disease diagnosis and treatment, supportive reimbursement policies, and the rising prevalence of diabetes are some of the main causes of the region's growth. Diabetes is on the rise in the United States at an alarming rate.

Government initiatives, an extensive number of R&D activities, and the improvement of healthcare providers' skill sets are factors that promote growth in the diabetes associated eye disorder market. When combined with patients' increasing awareness, it is anticipated that such supportive initiatives will result in profitable growth. By utilizing cutting-edge technology and using laser procedures with quick recoveries, the treatment of diabetic associated eye disorder market is anticipated to increase patient willingness for treatment.

Major Players

These include Novartis AG, Carl Zeiss Meditec AG, Alimera Sciences, Topcon Corporation, Bayer AG, and Regeneron Pharmaceuticals Inc.

Table of Contents:

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY 17

2 MARKET INTRODUCTION 19

2.1 DEFINITION 19

2.2 SCOPE OF THE STUDY 19

2.3 RESEARCH OBJECTIVE 19

2.4 MARKET STRUCTURE 20

3 RESEARCH METHODOLOGY 21

3.1 INTRODUCTION 21

3.2 DATA FLOW 23

3.2.1 DATA MINING PROCESS 23

3.3 PURCHASED DATABASE: 24

3.4 SECONDARY SOURCES: 25

3.4.1 SECONDARY RESEARCH DATA FLOW: 26

3.5 PRIMARY RESEARCH: 27

3.5.1 PRIMARY RESEARCH DATA FLOW: 28

3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 29

3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE Error! Bookmark not defined.

3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 30

3.6.1 REVENUE ANALYSIS APPROACH 30

3.7 DATA FORECASTING 30

3.7.1 DATA FORECASTING TECHNIQUE 31

3.8 DATA MODELING 32

3.8.1 MICROECONOMIC FACTOR ANALYSIS: 32

3.8.2 DATA MODELING: 33

3.9 TEAMS AND ANALYST CONTRIBUTION 34

4 MARKET DYNAMICS 36

4.1 INTRODUCTION 36

4.2 DRIVERS 37

4.2.1 INCREASING PREVALENCE OF DIABETES 37

4.2.2 RISE IN GOVERNMENT INITIATIVES 37

4.3 RESTRAINTS 39

4.3.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS 39

4.4	OPPORTUNITY	40
4.4.1	GROWING NUMBER OF KEY PLAYERS AND APPROVAL OF TREATMENT	40
5	MARKET FACTOR ANALYSIS	41
5.1	VALUE CHAIN ANALYSIS	41
5.1.1	R&D	42
5.1.2	MANUFACTURING	42
5.1.3	DISTRIBUTION AND SALES	42
5.1.4	POST-SALES MONITORING	42
5.2	PORTER'S FIVE FORCES MODEL	43
5.2.1	THREAT OF NEW ENTRANTS	43
5.2.2	BARGAINING POWER OF SUPPLIERS	44
5.2.3	THREAT OF SUBSTITUTES	44
5.2.4	BARGAINING POWER OF BUYERS	44
5.2.5	INTENSITY OF RIVALRY	44
5.3	COVID-19 IMPACT ANALYSIS	45
5.3.1	OVERVIEW	45
5.4	PREMIUM INSIGHTS	46
5.4.1	ANTI-VEGF FAILURES	46
5.4.2	IMPACT OF AI IN RETINAL SCREENING	46
5.4.3	LIMITATIONS DUE TO DEARTH OF OPHTHALMOLOGY MD SPECIALISTS	47
6	US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE TYPE	49
6.1	INTRODUCTION	49
6.2	DIABETIC RETINOPATHY	51
6.2.1	MILD NONPROLIFERATIVE STAGE	52
6.2.2	MODERATE NONPROLIFERATIVE STAGE	52
6.2.3	SEVERE NONPROLIFERATIVE STAGE	52
6.2.4	PROLIFERATIVE DIABETIC	53
6.3	DIABETIC MACULAR EDEMA (DME)	53
7	US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY DISEASE & TREATMENT	54
7.1	INTRODUCTION	54
7.2	DIAGNOSIS	56
7.2.1	FLUORESCEIN ANGIOGRAPHY	57
7.2.2	OPTICAL COHERENCE TOMOGRAPHY (OCT)	57
7.2.3	OPHTHALMOSCOPY	58
7.2.4	SLIT LAMP BIOMICROSCOPY	58
7.2.5	OTHERS	58
7.3	TREATMENT	59
7.3.1	ANTI-VEGF	59
7.3.2	INTRAOCULAR STEROID INJECTION	60
7.3.3	LASER SURGERY	60
7.3.4	VITRECTOMY	60
8	US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY END USER	61
8.1	INTRODUCTION	61
8.2	HOSPITAL & CLINICS	63
8.3	OPHTHALMIC CENTERS	63
8.4	OTHERS	63
9	US AND EU DIABETES ASSOCIATED EYE DISORDERS MARKET, BY REGION	64

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.1	INTRODUCTION	64
9.2	US	65
9.3	EUROPE	68
9.3.1	GERMANY	72
9.3.2	FRANCE	74
9.3.3	UK	76
9.3.4	ITALY	78
9.3.5	SPAIN	80
9.3.6	REST OF EUROPE	82
10	COMPETITIVE LANDSCAPE	85
10.1	INTRODUCTION	85
10.2	MARKET SHARE ANALYSIS, 2022	85
10.3	COMPETITOR DASHBOARD	86
10.4	PUBLIC PLAYERS STOCK SUMMARY	87
10.5	COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL	87
10.6	KEY DEVELOPMENTS & GROWTH STRATEGIES	88
10.6.1	PRODUCT LAUNCH/PRODUCT APPROVAL	88
10.6.2	MERGER AND ACQUISITION	88
10.6.3	PARTNERSHIP/INVESTMENT	89
11	COMPANY PROFILES	90
11.1	NOVARTIS AG	90
11.1.1	COMPANY OVERVIEW	90
11.1.2	FINANCIAL OVERVIEW	91
11.1.3	PRODUCTS OFFERED	91
11.1.4	KEY DEVELOPMENTS	92
11.1.5	SWOT ANALYSIS	92
11.1.6	KEY STRATEGY	92
11.2	GENENTECH, INC.	93
11.2.1	COMPANY OVERVIEW	93
11.2.2	FINANCIAL OVERVIEW	93
11.2.3	PRODUCTS OFFERED	93
11.2.4	KEY DEVELOPMENTS	94
11.2.5	SWOT ANALYSIS	94
11.2.6	KEY STRATEGY	94
11.3	CARL ZEISS MEDITEC AG	95
11.3.1	COMPANY OVERVIEW	95
11.3.2	FINANCIAL OVERVIEW	96
11.3.3	PRODUCTS OFFERED	96
11.3.4	KEY DEVELOPMENTS	97
11.3.5	SWOT ANALYSIS	98
11.3.6	KEY STRATEGIES	98
11.4	DIGITAL DIAGNOSTICS, INC.	99
11.4.1	COMPANY OVERVIEW	99
11.4.2	FINANCIAL OVERVIEW	99
11.4.3	PRODUCTS OFFERED	99
11.4.4	KEY DEVELOPMENTS	100
11.4.5	KEY STRATEGIES	100

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.5	BAYER AG	101
11.5.1	COMPANY OVERVIEW	101
11.5.2	FINANCIAL OVERVIEW	102
11.5.3	PRODUCTS OFFERED	102
11.5.4	KEY DEVELOPMENTS	102
11.5.5	SWOT ANALYSIS	103
11.5.6	KEY STRATEGIES	103
11.6	REGENERON PHARMACEUTICALS INC	104
11.6.1	COMPANY OVERVIEW	104
11.6.2	FINANCIAL OVERVIEW	105
11.6.3	PRODUCTS OFFERED	105
11.6.4	KEY DEVELOPMENTS	106
11.6.5	SWOT ANALYSIS	106
11.6.6	KEY STRATEGIES	107
11.7	AMPIO PHARMACEUTICALS INC	108
11.7.1	COMPANY OVERVIEW	108
11.7.2	FINANCIAL OVERVIEW	108
11.7.3	PRODUCTS OFFERED	108
11.7.4	KEY DEVELOPMENTS	109
11.7.5	KEY STRATEGIES	109
11.8	TOPCON CORPORATION	110
11.8.1	COMPANY OVERVIEW	110
11.8.2	FINANCIAL OVERVIEW	111
11.8.3	DISEASE TYPES OFFERED	112
11.8.4	KEY DEVELOPMENTS	112
11.8.5	SWOT ANALYSIS	113
11.8.6	KEY STRATEGY	113
11.9	ALIMERA SCIENCES	114
11.9.1	COMPANY OVERVIEW	114
11.9.2	FINANCIAL OVERVIEW	115
11.9.3	PRODUCTS OFFERED	115
11.9.4	KEY DEVELOPMENTS	116
11.9.5	KEY STRATEGY	116
11.10	GEUDER AG	117
11.10.1	COMPANY OVERVIEW	117
11.10.2	FINANCIAL OVERVIEW	117
11.10.3	PRODUCTS OFFERED	117
11.10.4	KEY DEVELOPMENTS	118
11.10.5	KEY STRATEGY	118
12	DATA CITATIONS	119

?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

US AND Europe Diabetes Associated Eye Disorders Market Research Report Forecast to 2030

Market Report | 2023-12-24 | 122 pages | Market Research Future

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$2950.00
	Enterprisewide Price	\$5250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-06"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com